ASTELLAS PHARMA (ALPMY)

15.80
0.01 0.06
OTC
Prev Close 15.79
Open 15.79
Day Low/High 15.79 / 15.88
52 Wk Low/High 12.41 / 16.70
Volume 33.85K
Exchange OTC
Shares Outstanding 1979.82B
Market Cap 30.97B
Div & Yield N.A. (N.A)

Latest News

Astellas Receives Positive CHMP Opinion For XOSPATA® (gilteritinib) As A Monotherapy For Patients With Relapsed Or Refractory Acute Myeloid Leukemia With A FLT3 Mutation

Astellas Receives Positive CHMP Opinion For XOSPATA® (gilteritinib) As A Monotherapy For Patients With Relapsed Or Refractory Acute Myeloid Leukemia With A FLT3 Mutation

If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for AML over the past 40 years(1)

Evrenzo® (roxadustat) Tablets Approved In Japan For The Treatment Of Anemia Associated With Chronic Kidney Disease In Dialysis Patients

Evrenzo® (roxadustat) Tablets Approved In Japan For The Treatment Of Anemia Associated With Chronic Kidney Disease In Dialysis Patients

TOKYO and SAN FRANCISCO, Sept. 20, 2019 /PRNewswire/ -- Astellas Pharma Inc.

Seattle Genetics And Astellas Announce U.S. FDA Grants Priority Review For Enfortumab Vedotin Biologics License Application In Locally Advanced Or Metastatic Urothelial Cancer

Seattle Genetics And Astellas Announce U.S. FDA Grants Priority Review For Enfortumab Vedotin Biologics License Application In Locally Advanced Or Metastatic Urothelial Cancer

- Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 -

Astellas Partners With MBC BioLabs To Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery And Research Efforts

Astellas Partners With MBC BioLabs To Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery And Research Efforts

Supporting pre-clinical scientific research: "Golden Ticket" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review For The Treatment Of Men With Metastatic Hormone-Sensitive Prostate Cancer

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review For The Treatment Of Men With Metastatic Hormone-Sensitive Prostate Cancer

XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy

Astellas Initiates Phase 3 Clinical Trials For Fezolinetant In Postmenopausal Women With Vasomotor Symptoms

Astellas Initiates Phase 3 Clinical Trials For Fezolinetant In Postmenopausal Women With Vasomotor Symptoms

TOKYO, Aug. 6, 2019 /PRNewswire/ -- Astellas Pharma Inc.

Astellas And Seattle Genetics Announce Submission Of Biologics License Application To FDA For Enfortumab Vedotin For Patients With Locally Advanced Or Metastatic Urothelial Cancer

Astellas And Seattle Genetics Announce Submission Of Biologics License Application To FDA For Enfortumab Vedotin For Patients With Locally Advanced Or Metastatic Urothelial Cancer

-Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology-

Astellas Appoints Chelsea Glinski As National Vice President Oncology Sales

Astellas Appoints Chelsea Glinski As National Vice President Oncology Sales

Glinski to Oversee US Sales for XTANDI

Astellas And Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate Of 44 Percent In Patients With Most Common Type Of Advanced Urothelial (Bladder) Cancer

Astellas And Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate Of 44 Percent In Patients With Most Common Type Of Advanced Urothelial (Bladder) Cancer

-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data For XOSPATA® (gilteritinib)

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data For XOSPATA® (gilteritinib)

- Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy[1] -

New Data Show Mirabegron Reduced OAB Symptoms In Men With Benign Prostatic Hyperplasia Currently Treated With Tamsulosin

New Data Show Mirabegron Reduced OAB Symptoms In Men With Benign Prostatic Hyperplasia Currently Treated With Tamsulosin

- Data Presented at the American Urological Association 2019 Annual Meeting -

A Very Happy New Year for Investors in Japan

A Very Happy New Year for Investors in Japan

The Nikkei 225 closed with a gain for 2016, making a run of five consecutive higher year-end closes -- the first since the 1990 bubble.

Sanofi Threatens to go Hostile in Medivation Battle

Sanofi Threatens to go Hostile in Medivation Battle

France's Sanofi said it would move to oust the current board of Medivation if the latter does not engage in discussions about a transaction.

Will a Third Medivation Suitor Present Itself?

Will a Third Medivation Suitor Present Itself?

Pfizer reportedly made a bid for the cancer drug maker, rivaling Sanofi's $9.3 billion offer, but analysts say another company might be the best fit.

Sanofi First Quarter Shows Why It Wants but Doesn't Need Medivation

Sanofi First Quarter Shows Why It Wants but Doesn't Need Medivation

The San Francisco target rejects the $9.3 billion offer, but biotech growth and a healthy pipeline mean Sanofi isn't desperate for Medivation's cancer treatments.

Sanofi Presses Medivation to Hold Talks After $9.3B Offer

Sanofi Presses Medivation to Hold Talks After $9.3B Offer

The French pharmaceuticals company takes its campaign to snare the oncology specialist public.

Medivation Jumps After Reportedly Hiring Bankers To Fight Takeover

Medivation Jumps After Reportedly Hiring Bankers To Fight Takeover

Shares of Medivation are rallying after Bloomberg reported the company is working with advisers to defend itself against a potential takeover.